Circulating Fibroblast Growth Factors as Metabolic Regulators—A Critical Appraisal
Authors:
- Bo AngelinBABo Angelin
- Tobias E. LarssonTLTobias E. Larsson
- Mats RudlingMRMats Rudling
- 1 December 2012
- journal article
- review article
- Published by Elsevier in Cell Metabolism
- Vol. 16 (6) , 693-705
Abstract
No abstract availableKeywords
This publication has 112 references indexed in Scilit:
- Update on fibroblast growth factor 23 in chronic kidney diseaseKidney International, 2012
- Fibroblast Growth Factor 19 and 7α-Hydroxy-4-Cholesten-3-one in the Diagnosis of Patients With Possible Bile Acid DiarrheaClinical and Translational Gastroenterology, 2012
- Fibroblast Growth Factor 23 and Risks of Mortality and End-Stage Renal Disease in Patients With Chronic Kidney DiseaseJAMA, 2011
- FGF15/19 Regulates Hepatic Glucose Metabolism by Inhibiting the CREB-PGC-1α PathwayCell Metabolism, 2011
- Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and diseaseCell and tissue research, 2010
- Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the communityAtherosclerosis, 2009
- Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7α‐hydroxylase gene expression†Hepatology, 2008
- The fasting polypeptide FGF21 can enter brain from bloodPeptides, 2007
- Endocrine Regulation of the Fasting Response by PPARα-Mediated Induction of Fibroblast Growth Factor 21Cell Metabolism, 2007
- Klotho converts canonical FGF receptor into a specific receptor for FGF23Nature, 2006